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Enzymes CYP4A11 and CYP4F2 are involved in biosynthesis of vasoactive 20-hydroxyeicosatetraenoic acid and may contribute to
pathogenesis of coronary artery disease (CAD). We investigated whether polymorphisms of the CYP4A11 and CYP4F2 genes are
associated with the risk of CAD in Russian population. DNA samples from 1323 unrelated subjects (637 angiographically
conﬁrmed CAD patients and 686 age- and sex-matched healthy individuals) were genotyped for polymorphisms rs3890011,
rs9332978, and rs9333029 of CYP4A11 and rs3093098 and rs1558139 of CYP4F2 by using the Mass-ARRAY 4 system. SNPs
rs3890011 and rs9332978 of CYP4A11 were associated with increased risk of CAD in women: OR= 1.26, 95% CI: 1.02–1.57, P =
0 004, and Q = 0 01 and OR= 1.45, 95% CI: 1.13–1.87, P = 0 004, and Q = 0 01, respectively. Haplotype G-C-A of CYP4A11 was
associated with increased risk of CAD (adjusted OR= 1.41, 95% CI: 1.12–1.78, and P = 0 0036). Epistatic interactions were
found between rs9332978 of CYP4A11 and rs1558139 of CYP4F2 (Pinteraction = 0 025). In silico analysis allowed identifying that
SNP rs9332978 is located at a binding site for multiple transcription factors; many of them are known to regulate the pathways
involved in the pathogenesis of CAD. This is the ﬁrst study in Europeans that reported association between polymorphism
rs9332978 of CYP4A11 and susceptibility to coronary artery disease.
1. Introduction
Coronary artery disease (CAD) is a common cardiovascular
disorder (CVD), a major cause of mortality and disability
in Russia and worldwide [1, 2]. CAD is a multifactorial
polygenic disorder resulting from complex interactions
between multiple genetic and environmental factors [3, 4].
Advances in molecular genetic and biochemical techniques
have improved our understanding of the metabolic disorders
causing CVD and coronary atherosclerosis, and the identiﬁ-
cation of candidate genes responsible for CAD susceptibility
is now an area of intense research interest. Genome-wide
association studies (GWAS) have provided powerful tools
to dissect genetic determinants of complex multifactorial
disorders and to identify new potential genes that may
increase the risk of coronary artery disease. Meta-analyses
of the largest GWAS conducted on coronary artery disease
have identiﬁed a number of genes associated with disease
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susceptibility in diﬀerent populations and provided insights
into the molecular basis of the disease [5, 6].
Genetically determined alterations in the metabolism
of arachidonic acid (AA) have been implicated in the
pathogenesis of CVD such as hypertension, atherosclerosis,
and coronary artery disease [7–10]. Arachidonic acid is
metabolized by various enzymes such as cyclooxygenases,
lipoxygenases, and cytochrome P450 monooxygenases pro-
ducing a variety of bioactive substances such as prostanoids,
leukotrienes, hydroxyeicosatetraenoic acids (HETEs), and
epoxyeicosatrienoic acids (EETs) [11, 12]. EETs are products
of cytochrome P450 epoxygenases that realize their cardio-
vascular eﬀects through activating receptor-mediated
signaling pathways and ion channels and possess vasodila-
tory, angiogenic, and anti-inﬂammatory properties in the
cardiovascular system [7, 8, 13, 14]. 20-HETEs (20-hydro-
xyeicosatetraenoic acids) are vasoactive eicosanoids which
are derived from the ω-hydroxylation of AA by members
of the CYP4 gene family and known to be involved in
the regulation of vascular tone and sodium transport in
the kidney [10, 15]. 20-HETEs possess multifaceted eﬀects
on cardiovascular functions including those implicated to the
pathogenesis of CVD: stimulation of smooth muscle contrac-
tility, migration, and proliferation, as well as activation of
endothelial cell dysfunction, angiogenesis, and inﬂammation
[9, 15]. Cytochrome P450 4A11 and 4F2 are the major
20-HETE-producing CYP4 isoforms in humans [16, 17]
which also participate in the metabolism of several drugs
including those used for therapy of CVDs [18].
Various studies have revealed that single nucleotide
polymorphisms (SNPs) in CYP4A11 and CYP4F2 have an
impact on expression or catalytic activity of these enzymes,
thereby contributing to the molecular basis of cardiovascular
disorders including CAD [17, 19–24]. Many of these studies
have discovered an association between some of these SNPs
and the susceptibility to hypertension and coronary artery
disease, making CYP4A11 and CYP4F2 reasonable candidate
genes for altering the risk of CVD. However, the results of
these studies were variable and sometimes contradictory that
may arise from diﬀerences in ethnic backgrounds, eﬀects of
environmental factors, or inconsistent inclusion criteria. A
huge portion of the studies conducted in Asian populations
have considered the CYP4F2 and CYP4A11 genes as candi-
dates for pharmacogenetic investigations of drugs. A limited
number of studies investigated the contribution of these
genes to the development of hypertension [17, 25, 26], and
no studies investigated the relationship of these genes with
CAD susceptibility in European populations. The purpose
of this study was to investigate whether common single
nucleotide polymorphisms in the CYP4A11 and CYP4F2
genes are associated with susceptibility to coronary artery
disease in Russian population.
2. Methods
2.1. Study Subjects. The study was approved by the Ethical
Review Committee of Kursk State Medical University, and
the participants who were recruited gave written informed
consent. A total of 1323 unrelated Russian subjects including
637 patients with coronary artery disease and 686 healthy
controls were enrolled from the Cardiology Divisions of
Kursk Regional Clinical Hospital and Kursk Emergency
Hospital as well as from the Regional Cardiovascular Centre
during a period between 2012 and 2015. All recruited
patients had clinical signs or a history of CAD (angina or
myocardial infarction) and angiographically conﬁrmed
coronary artery stenosis of >50%. CAD patients had no
clinical signs and/or histories of congenital heart disease,
cardiomyopathy, malignancy, connective-tissue disorder,
chronic inﬂammatory disease, and liver or kidney disease.
The control group included blood donors, healthy volunteers
without any chronic disease, and also hospital-based
patients having no clinical evidence for CAD or a history
of cerebrovascular/peripheral vessel disease. These subjects
were recruited over several periods in the framework of
our previous studies [27–29]. Demographic and clinical
data of the study participants are shown in Table 1. As
can be seen from Table 1, the study groups were matched
with respect to both sex and age (P > 0 05). A percentage
of positive family history of CAD, hypertension, and diabetes
was signiﬁcantly higher in the case group versus that in the
healthy controls. Biochemical parameters (blood lipids and
fasting glucose) were available from 347 subjects of the
control group. Signiﬁcant diﬀerences between the groups
were seen regarding the lipid parameters and blood glucose
concentration (Table 1).
2.2. Selection of Single Nucleotide Polymorphisms. Six
common SNPs such as rs3890011, rs1126742, rs9332978,
and rs9333029 of the CYP4A11 gene and rs3093098 and
rs1558139 of the CYP4F2 gene were selected for the study
based on their known functional relevance, haplotype tag-
ging properties, and previously reported associations with
cardiovascular diseases [21, 22, 24]. The functionality of the
selected SNPs and their haplotype properties were assessed
in silico by the SNP Function Prediction tool developed by
Xu and Taylor [30] and available online at the SNPinfo
Web Server (https://snpinfo.niehs.nih.gov/snpinfo/). SNP
rs1126742 of CYP4A11 was excluded from the study because
of insuﬃcient genotyping call rate (<70%) for this
polymorphism.
2.3. Genotyping. Genomic DNA was isolated from 5ml of
peripheral blood samples obtained from all study partici-
pants using standard phenol/chloroform procedure. Poly-
merase chain reaction (PCR) was performed on the CFX96
Touch™ Real-Time PCR Detection System (Bio-Rad Labora-
tories, USA). SNP genotyping was performed using a
MALDI-TOF mass spectrometry iPLEX platform (Agena
Bioscience Inc., San Diego, CA, USA) at the Core Facility
“Medical Genomics” in the Research Institute of Medical
Genetics (Tomsk, Russia). Blind replicates were included
for quality control. Genotype data on SNPs rs9332978 and
rs9333029 of CYP4A11 were not available from two CAD
patients and two healthy controls, respectively.
2.4. Data Analysis.An association analysis between SNPs and
disease risk could detect a diﬀerence of 2–6% in the genotype
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distributions between the cases and controls assuming
81–92% statistical power and a 5% type I error (α = 0 05)
on the basis of the sample sizes of 637 CAD patients and
686 healthy controls. Allele frequencies were estimated by
the gene counting method, and the chi-square test was used
to assess signiﬁcant departures from Hardy–Weinberg equi-
librium (HWE). Categorical variables were also compared by
using the chi-square test. Allele, genotype, and haplotype fre-
quencies in the study groups were evaluated by the SNPassoc
package for R [31] and the SNPStats software [32]. The
strength of the association of the SNPs with the occurrence
of coronary artery disease was measured by multiple logistic
regression analysis to calculate odds ratios (OR) with 95%
conﬁdence intervals (CI) and adjusted for confounding
factors. Epistatic interactions between SNPs (log-likelihood
ratio test (LRT)) were analyzed by the SNPassoc package
for R [31], assuming codominant, dominant, and recessive
models, and adjusted for age, gender, and hypertension.
Haplotypes of CYP4A11 and CYP4F2 were estimated in the
entire groups of CAD patients and controls by the SNPStats
software. P value ≤ 0.05 was set to be statistically signiﬁcant.
As an adjustment for multiple testing, false discovery rate-
(FDR-) based Q value was calculated for each SNP using
the method proposed by Benjamini and Hochberg [33]
and implemented in the FDR calculator available online
at http://www.sdmproject.com/utilities/?show=FDR. Signif-
icance of the associations was assessed by a 0.20 threshold
of Q value, as previously suggested [34]. The regulatory
potential of the studied SNPs was evaluated by the SNP
Function Prediction tool [30] using the TRANSFAC data-
base on potential transcription factor recognition sites
(BIOBASE Corporation, Wolfenbuettel, Germany) as well
as by using the rSNPBase database of curated regulatory
SNPs (http://rsnp.psych.ac.cn) [35].
3. Results
3.1. Association Study between the CYP4A11 and CYP4F2
SNPs and CAD Risk. The genotype and allele frequencies of
CYP4A11 and CYP4F2 SNPs are shown in Table 2. A signif-
icant departure from Hardy–Weinberg equilibrium (HWE)
was observed for SNP rs9333029 of CYP4A11: no individuals
with homozygous genotype GG were identiﬁed among the
study participants. Notably, frequencies of genotypes AA
and AG were compatible with those reported in various
European populations, and genotype GG is also uncommon
among Europeans (the 1000 Genomes Project, http://www.
internationalgenome.org). Allele and genotype frequencies
of other SNPs were similar with those observed in other
European populations. As can be seen from Table 2, poly-
morphism rs9332978 of CYP4A11was found to be associated
with increased risk of coronary artery disease at codominant
genetic model after adjustment for confounding factors. In
particular, the increased risk of CAD was associated with a
carriage of variant allele C (P = 0 002, Q = 0 01) and geno-
types T/C and CC (P = 0 008, Q = 0 04). In addition, allele
G of rs3890011 showed a signiﬁcant association with the risk
of CAD (P = 0 02, Q = 0 05). These associations remain
signiﬁcant after adjustment for multiple testing using the
FDR method. Table 3 shows gender-stratiﬁed distributions
of genotypes and alleles for the studied SNPs in the case
and control groups. The rs3890011 and rs9332978 polymor-
phisms of CYP4A11 were associated with the increased risk
of coronary artery disease exclusively in females (P = 0 004,
Q = 0 01).
3.2. Interactions between SNPs of CYP4A11 and CYP4F2.We
performed a log-likelihood ratio test to look for epistatic
interaction between SNPs (Table 4). As can be seen from
Table 1: Demographic and clinical data of the study participants.
Baseline characteristics Controls, n = 686 CAD patients, n = 637 P value
Age, mean ± SD 58.8 ± 7.6 59.5 ± 10.3 0.16
Males 404 (58.9) 401 (63.0) 0.13
BMI (kg/m2), mean ± SD 27.9 ± 10.2 28.8 ± 9.4 0.10
Hypertension 0 (0.0) 842 (90.2) —
Diabetes 0 (0.0) 79 (8.5) —
Fasting blood glucose (mmol/L)1 5.2± 0.7 8.1 ± 0.5 <0.0001
TC (mmol/L)1 4.2± 0.3 6.2 ± 0.4 <0.0001
HDL-C (mmol/L)1 1.2 ± 0.2 1.1 ± 0.3 <0.0001
LDL-C (mmol/L)1 3.1 ± 0.3 4.3 ± 0.6 <0.0001
TG (mmol/L)1 1.5 ± 0.4 1.7 ± 0.3 <0.0001
Smokers (ever/never)2 273 (41.5) 251 (43.5) 0.48
Positive family history of CAD 150 (23.8) 323 (34.6) <0.0001
Positive family history of hypertension 100 (15.9) 273 (29.2) <0.0001
Positive family history of diabetes 24 (3.8) 127 (13.6) <0.0001
1The biochemical parameters were available from 347 subjects of the control group. 2Data on smoking status were not available from 60 CAD patients and 28
controls. SD: standard deviation; BMI: body mass index (age and BMI were normally distributed and were analyzed by Student’s t-test); TC: total cholesterol;
HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglyceride. Other data are expressed as frequencies and
percentages and were evaluated by the χ2 test. Bolded is statistically signiﬁcant P value.
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Table 4, SNPs rs3890011 (P = 0 035) and rs9332978 (P =
0 004) of CYP4A11 showed signiﬁcant individual eﬀects
on CAD risk at a dominant genetic model. Notably, we
found epistatic interactions between rs9332978 of
CYP4A11 and rs1558139 of CYP4F2 (recessive model,
Pinteraction = 0 025) as well as between rs3093098 and
rs1558139 of the CYP4F2 gene (overdominant model,
Pinteraction = 0 047).
3.3. Analysis of Haplotypes and Linkage Disequilibrium
between SNPs. The three SNPs of the CYP4A11 gene and
the two SNPs of CYP4F2 were used to establish ﬁve haplo-
types. The patterns of estimated haplotypes and their
frequencies in the case and control groups are shown in
Table 5. Four haplotypes of CYP4A11 gene and three haplo-
types of CYP4F2 with a frequency> 1% have been identiﬁed
in the study patients. As can be seen from Table 5, the overall
distribution of the haplotypes of CYP4A11 was signiﬁ-
cantly diﬀerent between the CAD patients and the healthy
controls (P = 0 019). The frequency of the H2 (G-C-A)
haplotype was signiﬁcantly higher in the CAD patients
than that in the healthy controls (OR=1.42, 95% CI:
1.13–1.79, P = 0 003). Thus, the common G-C-A haplotype
was thought to be a susceptibility haplotype in CAD
patients. No signiﬁcant diﬀerence in the CYP4F2 haplo-
type frequencies was found between the case and control
groups (P > 0 05). Table 6 shows pairwise linkage disequilib-
rium coeﬃcients among the SNPs of CYP4A11. Polymor-
phism rs9332978 in the promoter of CYP4A11 was in
strong linkage disequilibrium to the intronic polymorphism
rs3890011 (D′ = 0 974, P < 0 0001). A strong linkage disequi-
librium was also found between SNPs rs3890011 and
rs9333029 of CYP4A11 (D′ = 0 955, P < 0 0001). Further-
more SNPs rs9332978 and rs9333029 are also in linkage dis-
equilibrium but with a lesser degree (D′ = 0 565, P < 0 0001).
3.4. In Silico Analysis of SNPs. Table 6 shows the results of
bioinformatic analysis for the regulatory potential of the
studied SNPs. The SNP Function Prediction tool allowed
identifying putative transcription factor binding sites (TFBS)
at SNP rs9332978 of CYP4A11 and SNP rs3093098 of
CYP4F2. In particular, 27 and 7 TFBSs were identiﬁed to
possess the potential impact on the gene expression through
a binding site located at SNP rs9332978 in the proximal
promoter of CYP4A11, as reported by the TRANSFAC data-
base and rSNPBase, respectively. As can be seen from Table 6
(detailed information on all transcription factor binding sites
identiﬁed is listed in Supplementary Tables 1 and 2),
polymorphism rs3890011 of CYP4A11 has the regulatory
potential and an experimentally proven eQTL (i.e., locus
controlling transcript levels of the gene). Moreover, SNPs
rs3093098 and rs1558139 of CYP4F2 fall into RNA binding
protein-mediated regulation sites.
4. Discussion
4.1. Variation in the CYP4A11 Gene and CAD Susceptibility.
CYP4A11 and CYP4F2 are highly polymorphic genes which
Table 2: Genotype and allele frequencies for SNPs of CYP4A11 and CYP4F2 in patients with CAD and healthy controls.
Gene, polymorphism Genotype, allele
Controls, n = 686
n (%)1
CAD patients, n = 637
n (%)1
OR (95% CI)2 P value Q value
CYP4A11, C>G (rs3890011)
C/C 404 (58.9) 338 (53.1) 1.00
0.086 0.22C/G 236 (34.4) 244 (38.3) 1.21 (0.91–1.58)
G/G 46 (6.7) 55 (8.6) 1.40 (0.92–2.23)
G 328 (23.9) 354 (27.8) 1.21 (1.02–1.48) 0.02 0.05
CYP4A11, T>C (rs9332978)
T/T 542 (79) 459 (72.3) 1.00
0.008 0.04T/C 134 (19.5) 158 (24.9) 1.42 (1.09–1.84)
C/C 10 (1.5) 18 (2.8) 2.26 (1.04–4.95)
C 154 (11.2) 194 (15.3) 1.44 (1.16–1.81) 0.002 0.01
CYP4A11, A>G (rs9333029)
A/A 526 (76.9) 477 (74.9) 1.00
0.43 0.72A/G 158 (23.1) 160 (25.1) 1.09 (0.78–1.59)
G/G 0 (0.0) 0 (0.0) —
G 158 (11.5) 160 (12.6) 1.04 (0.80–1.43) 0.42 0.70
CYP4F2, A>G (rs3093098)
A/A 479 (69.8) 448 (70.3) 1.00
0.89 0.91A/G 186 (27.1) 172 (27) 0.97 (0.76–1.27)
G/G 21 (3.1) 17 (2.7) 0.85 (0.43–1.68)
G 228 (16.6) 206 (16.2) 0.96 (0.80–1.17) 0.76 0.76
CYP4F2, G>A (rs1558139)
G/G 200 (29.1) 192 (30.1) 1.00
0.91 0.91G/A 336 (49) 312 (49) 0.98 (0.73–1.28)
A/A 150 (21.9) 133 (20.9) 0.94 (0.70–1.29)
A 636 (46.4) 578 (45.4) 0.97 (0.80–1.18) 0.61 0.76
1Absolute number and percentage of individuals/chromosomes with particular genotype/allele. 2Odds ratio with 95% conﬁdence intervals adjusted for age,
gender, BMI, hypertension, diabetes, and smoking.
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became attractive candidates for association studies of
cardiovascular diseases. A number of these studies have been
done in Asian populations, and no studies investigated the
contribution of the genes to coronary artery disease suscepti-
bility in Europeans. In addition, the results of these studies
were variable and sometimes contradictory, thus justifying
the need for further investigations of the relationship
between CYP4A11 and CYP4F2 gene polymorphisms and
CAD risk in independent racial and ethnic groups.
SNP T8590C (rs1126742) is the most extensively investi-
gated polymorphism in the CYP4A11 gene that has been
shown to be associated with the level of blood pressure and
hypertension susceptibility [17, 36] as well as with endothe-
lial dysfunction in the coronary arteries in patients with
Table 4: Epistatic interactions between the CYP4A11 and CYP4F2 genes in CAD (gene-gene interactions are evaluated by SNPassoc package
for R [31]).
SNPs
Genetic
models
CYP4A11
(rs3890011)
CYP4A11
(rs9332978)
CYP4A11
(rs9333029)
CYP4F2
(rs3093098)
CYP4F2
(rs1558139)
CYP4A11 (rs3890011)
Сodominant 0.086 0.459 0.725 0.598 0.435
Dominant 0.035 0.712 0.450 0.319 0.533
Recessive 0.180 0.159 — 0.986 0.594
Overdominant 0.152 0.879 0.168 0.899 0.844
CYP4A11 (rs9332978)
Сodominant 0.933 0.008 0.396 0.194 0.226
Dominant 0.768 0.004∗ 0.885 0.156 0.512
Recessive 0.608 0.063 — — 0.025
Overdominant 0.824 0.019 0.935 0.307 0.686
CYP4A11 (rs9333029)
Сodominant 0.477 0.371 0.433 0.902 0.216
Dominant 0.534 0.398 0.433 0.835 0.098
Recessive — — — — —
Overdominant 0.899 0.441 0.433 0.743 0.134
CYP4F2 (rs3093098)
Сodominant 0.849 0.837 0.866 0.894 0.096
Dominant 0.627 0.592 0.711 0.775 0.152
Recessive 0.675 0.703 — 0.661 —
Overdominant 0.808 0.718 0.838 0.897 0.047
CYP4F2 (rs1558139)
Сodominant 0.890 0.923 0.918 0.806 0.912
Dominant 0.715 0.807 0.718 0.668 0.733
Recessive 0.701 0.764 — 0.686 0.717
Overdominant 0.998 0.913 0.940 0.991 0.989
The upper part of the matrix contains the P values for epistatic interactions evaluated by log-likelihood ratio (LRT) test. The diagonal contains the P values from
LRT for the crude eﬀect of each SNP. The lower triangle contains the P values from LRT comparing the two-SNP additive likelihood to the best of the single-
SNP models. Bolded are statistically signiﬁcant P values for SNP-SNP interactions (∗most signiﬁcant P value for a particular model). P values are adjusted for
age and gender.
Table 5: Estimated haplotype frequencies of CYP4A11 in CAD patients and controls.
Haplotypes1 Controls CAD patients OR (95% CI)2 P value
SNPs C>G (rs3890011), T>C (rs9332978), and A>G (rs9333029) of CYP4A11
H1 C-T-A 0.7549 0.7158 1.00 —
H2 G-C-A 0.1060 0.1433 1.41 (1.12–1.78) 0.0036
H3 G-T-G 0.1087 0.1146 1.15 (0.88–1.50) 0.30
H4 G-T-A 0.0207 0.0135 0.67 (0.37–1.22) 0.19
Global haplotype association P value: 0.021
SNPs A>G (rs3093098) and G>A (rs1558139) of CYP4F2
H1 A-A 0.4636 0.4525 1.00 —
H2 A-G 0.3703 0.3858 1.05 (0.91–1.27) 0.49
H3 G-G 0.1662 0.1605 0.97 (0.78–1.24) 0.85
Global haplotype association P value: 0.72
1Rare haplotypes with frequency < 0.01 are not shown. 2Odds ratio with 95% conﬁdence intervals adjusted for age, gender, BMI, diabetes, and hypertension.
Bolded is statistically signiﬁcant P value.
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CAD in Europeans [37]. Another SNP rs3890011 in intron
of CYP4A11 was also a subject of investigations in cardio-
vascular disorders in various populations of the world. In
particular, a study in Chinese population did not identify
the link of the rs3890011 polymorphism with blood
pressure variation and hypertension susceptibility [38].
However, Fu with coworkers have revealed a signiﬁcant
association between SNP rs3890011 and the risk of CAD,
but the association occurred only in males [24]. This study
did not observe an association between a promoter polymor-
phism rs9332978 of CYP4A11 and CAD risk. The authors
also reported that the functional eﬀect of the rs3890011
polymorphism is related to neighboring functional SNPs
(possibly rs9332978), potentially aﬀecting the structure
and/or catalytic activity of the enzyme [24].
The present study was designed to investigate whether
common SNPs rs3890011, rs1126742, rs9332978, and
rs9333029 of CYP4A11 and rs3093098 and rs1558139
CYP4F2 are associated with the risk of CAD in Russian
population. The present study has revealed that polymor-
phisms rs3890011 and rs9332978 are both associated with
the risk of CAD; however, the association occurred only in
females. Interestingly, these SNPs represent a part of com-
mon functional haplotype ofCYP4A11, as it has been demon-
strated by our and some other studies [23, 39]. In particular,
haplotype G-G-T (rs9332978, rs3890011, rs1126742) was
found to be moderately associated with the CAD risk in
Chinese Han population, whereas SNP rs9332978 alone did
not show a signiﬁcant association with disease risk [39]. We
found that the high CAD risk haplotype G-C-A (rs3890011,
rs9332978, and rs9333029; risk alleles are underlined) in
our patients coincides with a part of haplotype G-C-T
(rs3890011, rs9332978, rs1126742) reported as the disease
risk haplotype in the study of Fu with coworkers [39]. It
seems reasonable to say that the functional eﬀect of this
haplotype on enzyme’s activity could be related with varia-
tion in the proximal promoter of CYP4A11, that is, with
SNP rs9332978. At least, this suggestion may be supported
by the study in Japanese population that reported a relation-
ship between the SNP rs9332978, expression of CYP4A11,
and the hypertension risk [40]. Sugimoto et al. [40] observed
that the −845GG genotype is associated with lower pro-
moter activity when compared with −845AA genotype,
and allele −845G was positively correlated to hypertension
susceptibility. Additionally, the authors [40] supposed that
the rs9332978 polymorphism falls into DNA binding site
for an unidentiﬁed protein and/or potential transcription
factor. The bioinformatic analysis for the regulatory potential
of investigated polymorphisms allowed us identifying puta-
tive transcription factor binding sites at SNP rs9332978 of
the CYP4A11 gene. Interestingly, it was found that the
DNA binding site located at this SNP may be regulated by
numerous transcription factors representing the pathways
being involved into the molecular mechanisms of coronary
atherosclerosis. In particular, CEBPB is an important tran-
scription factor binding to promoter regions of multiple
inﬂammatory response genes, synergistically upregulating
and sustaining their expression after inﬂammatory stimula-
tion [41, 42]. HNF4A (hepatocyte nuclear factor 4 alpha) is
a transcriptionally controlled transcription factor that
binds to DNA sites required for the transcription of alpha
1-antitrypsin, apolipoprotein CIII, transthyretin genes, and
HNF1-alpha (data obtained from the UniProtKB). In
accordance with Gene Ontology descriptions (GO, http://
www.geneontology.org), HNF4A has the potential to
coregulate genes involved in blood coagulation, lipid
homeostasis (positive regulation of cholesterol homeosta-
sis), cell proliferation, and other important biological pro-
cesses which play a role in the pathogenesis of CAD.
Altogether, these data make SNP rs9332978 of CYP4A11
a subject of great interest for further research of molecular
pathogenesis of coronary artery disease.
4.2. Possible Role of SNP rs9332978 of CYP4A11 in the
Pathogenesis of CAD. Literature data on a relationship
between decreased 20-HETEs and pathogenesis of cardiovas-
cular disease are extremely limited. Nevertheless, based on
available publications, the UniProtKB database and Gene
Ontology descriptions, we proposed the mechanisms by
which loss-of-function polymorphisms rs9332978 and
rs1126742 of CYP4A11 are associated with reduced 20-
HETE synthase activity and increased risk of coronary artery
disease (Figure 1). 20-HETE is a potent endogenous ago-
nist of PPARα (peroxisome proliferator-activated receptor
alpha) [43]. The peroxisome proliferator-activated receptors
are ligand-activated transcription factors belonging to the
nuclear hormone receptor superfamily. Bioinformatic analy-
sis allowed us identifying a binding site at SNP rs9332978
for transcription factor PPARG as a potent coregulator
of CYP4A11 gene expression (Table 6). Importantly, PPARα
is a major regulator of intra- and extracellular lipid metabo-
lism [44]. PPARα and PPARG serve as physiological sensors
of lipid levels whereby dietary fatty acids can modulate lipid
homeostasis [45]. PPARα activation can increase the levels
of HDL-C through increasing concentration of apo A-I and
A-II and through stimulating the reverse cholesterol trans-
port pathway [46]. Hence, a deﬁciency of 20-HETE may
reduce the hypolipidemic eﬀects of PPARα, leading to
decreased HDL-C and hypercholesterolemia. Moreover,
activation of PPARα can exert anti-inﬂammatory eﬀects,
suppressing the acute-phase response and decreasing the
release of proinﬂammatory cytokines [47]. In addition, 20-
HETE was found to be a potent, dose-dependent inhibitor
of platelet aggregation and biosynthesis of thromboxane
A2, most probably by antagonizing the prostaglandin H2/
thromboxane A2 (PGH2/TXA2) receptor [48], thereby lead-
ing to increased formation of thrombi.
However, when interpreting genotype-phenotype corre-
lation, it is important to keep in mind that it is diﬃcult to
predict the consequences of a change in the activity of the
CYP4A11 enzyme, especially taking the dual role of 20-
HETE in vascular and renal homeostasis into consideration
[12, 15, 49]. Undoubtedly, this means that our suggestions
on the involvement of these SNPs in CAD pathogenesis
require experimental conﬁrmation. In addition, we cannot
rule out the possibility of complex interactions between
diﬀerent polymorphic genes and their comprehensive contri-
bution to the levels of 20-HETE in the heart and coronary
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arteries in patients with CAD. In this context, our interesting
ﬁnding was an epistatic interaction between SNP rs9332978
of CYP4A11 and SNP rs1558139 of CYP4F2 (this polymor-
phism was associated with the risk of essential hypertension
in Japanese population [19]) in CAD patients suggesting that
gene-gene interactions could be involved into the regulation
of 20-HETE metabolism and jointly contribute to the
development of coronary artery disease.
4.3. Gender-Speciﬁc Relationship between SNP rs9332978 of
CYP4A11 and Risk of CAD. Interestingly, the eﬀects of
rs9332978 of the CYP4A11 gene on CAD risk in our study
were evident only in women. This ﬁnding supports the
hypothesis that the interaction of sex hormones with expres-
sion cytochrome P450 enzymes involved in the 20-HETE
metabolism could have a role in well-established sex dimor-
phism in the risk of cardiovascular disease [50]. It can be
assumed that association between rs9332978 of CYP4A11
and CAD susceptibility in women may be related with the
inhibitory eﬀect of estradiol on the CYP4A11 expression in
the carriers of the variant genotypes, leading to reduced syn-
thesis of 20-HETE and increasing the disease risk through
the mechanisms described above. Biosynthesis of 20-HETE
is regulated in age- and sex-dependent manner [15, 49, 51],
and CYP4A11 itself has a catalytic activity for the metabolism
of estrogens such as 17beta-estradiol and estrone [52, 53].
This means that estrogens may represent important modi-
ﬁers of CYP4A11-medicated metabolism of 20-HETE. The
study of White with coworkers provided evidence that
polymorphism in the CYP4A11 gene is related with disorders
underlying coronary atherosclerosis, and this relationship
is also sex speciﬁc [54]. In particular, polymorphism
rs1126742 of CYP4A11 was found to be associated with
HDL-C and C-reactive protein in women [54]. This relation-
ship may be explained by the eﬀects of PPARα agonists
which are known to improve lipid metabolism disorder,
and this capacity appears to be modulated by estrogens
[55]. White with coworkers proposed that the eﬀect of the
loss-of-function allele of CYP4A11 on decreased formation
of PPARα agonists could be magniﬁed in women [54]. SNP
rs9332978 of CYP4A11 is located within a binding site for
transcription factor FOXA1 (forkhead box A1 or hepatocyte
nuclear factor 3 alpha). Interestingly, FOXA1 modulates the
transcriptional activity of nuclear hormone receptors and is
involved in positive regulation of intracellular estrogen
receptor signaling pathway [56]. Apparently, female hor-
mones have the potential to bind with speciﬁc sites at the
promoter of CYP4A11 and therefore could be responsible
for sex-speciﬁc alterations in the expression of CYP4A11,
thereby aﬀecting the production of 20-HETE. The mecha-
nisms whereby estrogens exert their regulatory eﬀects on
CAD through the modulation of CYP4A11 gene expression
remained to be elucidated in further studies.
There are several limitations to address in the context
of the current results. First, we did not measure 20-HETE
levels in the study patients, and possible alterations in the
Modulation of CYP4A11
gene expressed by
estradiol (?)
Reduced 20-HETE synthase activity due to the
loss-of-function polymorphisms of CYP4A11
Decreased biosynthesis
of 20-HETE
Decreased activation of peroxisome proliferator-
activated receptor alpha
Vascular inammation,
endothelial dysfunction
Decreased levels of HDL-C,
hypercholesterolemia
Coronary heart disese
Decreased suppression of the
acute-phase response, increased
expression of proinammatory
cytokines such as TNF and IL1
Decreased
concentration of apo
A-1 and A11
Decreased stimulation of
the reverse cholesterol
transport pathway
Increased platelet
activation and
aggregation
Increased formation
of thrombi
Decreased inhibition of platelet aggregation
and formation of thromboxane A2
Figure 1: Proposed mechanisms by which the loss-of-function polymorphisms of the CYP4A11 gene are involved in the pathogenesis of
coronary heart disease (see the text for details).
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metabolism of arachidonic acid in CAD could not be
established in our study. Further studies are needed to
clarify the eﬀects of the investigated polymorphisms of
CYP4A11 on arachidonic acid metabolism and/or 20-
HETE production. Second, other polymorphisms in the
CYP4A11 gene such as those located in intronic regions or
distal promoter regions not investigated in this study
might also be associated with disease susceptibility.
Unfortunately, insuﬃcient genotyping call rate (<70%) for
polymorphism rs1126742 (T8590C) of CYP4A11 did not
allow the inclusion of this SNP into the study. In order to
describe the complete haplotype structure of the CYP4A11
gene, it is necessary to expend a spectrum of
polymorphisms in future studies. Third, potential interac-
tions of genetic polymorphisms of CYP4A11 and CYP4F2
with environmental conditions such as food and dietary
elements were unexplored in the study, thus not allowing
any conclusion to be drawn with respect to sex-speciﬁc
associations between the genes and disease risk.
5. Conclusions
The present study identiﬁed that polymorphism rs9332978
of CYP4A11 could be a novel marker of genetic susceptibility
to coronary artery disease, at least in Europeans. Moreover,
our study provided additional evidence that CYP4A11 is an
important susceptibility gene for coronary artery disease
despite the fact that diﬀerent polymorphisms of the gene
showed association with disease risk in various populations.
Although the molecular mechanisms underlying the
development of coronary artery disease in women
with the rs9332978 polymorphism of CYP4A11 remain to
be determined, the results of the present study support the
hypothesis that variation in the CYP4A11 gene is an
important determinant associated with the risk of
coronary artery disease in gender-speciﬁc manner. Further
eﬀorts should be made to address the function of the
studied SNPs of CYP4A11 in arachidonic acid metabolism
in order to determine the eﬀect of the polymorphisms on
the production of 20-HETE in the coronary arteries in CAD
patients. Nevertheless, the association between SNP
rs9332978 of CYP4A11 and the risk of coronary artery
disease provides insights into the molecular basis of disease
pathogenesis and suggests possible avenues in developing
novel drugs for pharmacological intervention in the
metabolism of 20-hydroxyeicosatetraenoic acids in
patients with CVD. Further pharmacogenomic studies are
needed to substantiate the contribution of CYP4A11
polymorphisms in the pathogenesis of coronary artery
disease and to assess the dual role of 20-
hydroxyeicosatetraenoic acids in cardiovascular homeosta-
sis as a promising target for vascular medicine in the
future.
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